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Abstract
Background: Mandelic acid (MA), an important component in pharmaceutical syntheses, is currently produced
exclusively via petrochemical processes. Growing concerns over the environment and fossil energy costs have
inspired a quest to develop alternative routes to MA using renewable resources. Herein we report the first direct
route to optically pure MA from glucose via genetic modification of the L-phenylalanine pathway in E. coli.
Results: The introduction of hydroxymandelate synthase (HmaS) from Amycolatopsis orientalis into E. coli led to a
yield of 0.092 g/L S-MA. By combined deletion of competing pathways, further optimization of S-MA production
was achieved, and the yield reached 0.74 g/L within 24 h. To produce R-MA, hydroxymandelate oxidase (Hmo)
from Streptomyces coelicolor and D-mandelate dehydrogenase (DMD) from Rhodotorula graminis were co-expressed
in an S-MA-producing strain, and the resulting strain was capable of producing 0.68 g/L R-MA. Finally,
phenylpyruvate feeding experiments suggest that HmaS is a potential bottleneck to further improvement in yields.
Conclusions: We have constructed E. coli strains that successfully accomplished the production of S- and R-MA
directly from glucose. Our work provides the first example of the completely fermentative production of S- and
R-MA from renewable feedstock.
Keywords: Escherichia coli, fermentation, fine chemicals, metabolic engineering, renewable resources, R-mandelic
acid, S-mandelic acid
Background
Mandelic acid (MA), an important fine chemical, has
been widely used in the synthesis of cephalosporin anti-
biotics [1], the preparation of various other pharmaceuti-
cals [2-4], as well as the resolution of racemic alcohols
and amines [5,6]. Its stereoisomers generally are prepared
using a chemical approach [7-9]. However, it has also
been reported that its stereoisomers can be prepared via
enzymatic routes; for example, stereospecific nitrilases
are used to produce S- or R-MA [10-13] and enantiose-
lective microbes are employed to degrade S-MA or
R-MA to yield R- or S-enantiomers [14-16], respectively.
In addition, a system combining the two microbes
Pseudomonas polycolor and Micrococcus freudenreichii
has also been explored for the production of R-MA from
the racemate [17]. However, these commodity chemicals
are manufactured entirely from petroleum-based feed-
stock such as benzaldehyde and mandelonitrile. Growing
concerns over the environment and fossil resources costs
have inspired a quest to develop more sustainable pro-
cesses that afford these products from renewable feed-
stock at lower cost. Thus, biological processes based on
renewable resources such as glucose that would provide
direct one-step production of chiral MA in a microbial
fermentation process would be of commercial interest.
Thus far, no direct biosynthetic pathway to free chiral
MA has been identified in nature, although some organ-
isms possess an MA catabolic pathway [18]. Engineering
a microbe for the production of a heterologous com-
pound requires the establishment of a new biochemical
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S-MA and R-MA in E. coli, two problems need to be
resolved. Firstly, suitable starting intermediates must be
available. Secondly, the introduction of enzymes catalyz-
ing reactions to produce the desired products must be
feasible.
Here we describe the construction of synthetic path-
ways for the production of S-MA and R-MA in E. coli by
combining biological entities from various organisms.
For the production of S-MA, 4-hydroxymandelate
synthase (HmaS) from Amycolatopsis orientalis was used
t oc o n v e r tp h e n y l p y r u v a t et oS - M A[ 1 9 ] .T oe x p a n dt h e
S-MA synthesis to produce R-MA, two other enzyme
reactions were explored: 4-hydroxymandelate oxidase
(Hmo) from Streptomyces coelicolor was used to convert
S-MA to phenylglyoxylate [19] and a third enzyme,
D-mandelate dehydrogenase (DMD) derived from
R. graminis, was used for the stereo-reduction of phenyl-
glyoxylate to R-MA [20]. As phenylpyruvate is the direct
precursor of L-phenylalanine, starting from phenylpyru-
vate it should be possible to construct an artificial path-
way using HmaS, Hmo, and DMD to biosynthesize chiral
MA directly from glucose in E. coli (Figure 1).
In this study, we have modified E. coli strains that suc-
cessfully achieved the production of S- and R-MA
directly from glucose. To our knowledge, this is the first
report describing the engineering of the L-phenylalanine
pathway in E. coli to produce enantiomerically pure
S-MA and R-MA directly from a renewable resource
such as glucose.
Results
Fermentation of glucose via expression of HmaS in E. coli
to produce S-MA directly
In order to construct a pathway to produce S-MA via a
modified L-phenylalanine pathway in E. coli, an enzyme
with S-mandelate synthesis activity is required to
convert phenylpyruvate to S-MA. Thus, HmaS from
A. orientalis was cloned and over-expressed in E. coli;
the specific activity of HmaS was determined to be
10.18 mU/mg total protein. Production of MA in the
reaction broth was identified by HPLC equipped with a
chiral column, and the results illustrated that HmaS was
able to convert phenylpyruvate to S-MA (Additional file
1), but not for the control (Additional file 1). Surpris-
ingly, trace amounts of R-MA were detected as well, the
results revealing that HmaS is not a rigorous stereo-
inverting enzyme for catalyzing phenylpyruvate to
S-MA. The enantiomeric excess (ee), > 98%, was calcu-
lated according to a previous report [15]. Therefore, this
enzyme could be used further for the preparation of
S-MA in E. coli.
Over-expressions of deregulated 3-deoxy-D-arabino-
heptulosonate-7-phosphate (DAHP) synthase and choris-
mate mutase/prephenate dehydratase are well known
strategies for increasing L-phenylalanine production in
E. coli [21]. In this study, both the feedback deregulated
DAHP synthase encoded by aroF
fbr [22] and chorismate
mutase/prephenate dehydratase encoded by pheA
fbr [23]
were constructed and over-expressed to increase the car-
bon flow into the shikimate pathway and ensure suffi-
cient flow from chorismate to phenylpyruvate. To allow
the fermentation of glucose to produce S-MA, an artifi-
cial operon with aroF
fbr,p h e A
fbr and hmaS over-expres-
sion was created, which resulted in the recombinant
plasmid pSUFAAQ (Figure 2A).
To produce S-MA in E. coli, wild-type strains of E. coli
W3110 harboring pSUFAAQ were cultured in fermenta-
tion medium in shake flasks. This resulted in the produc-
tion of 0.092 g/L S-MA within 24 h, and a large amount
of L-phenylalanine was detected as well. This proved that
the artificial operon was functionally expressed in E. coli.
Therefore, this strain could be used as a basis strain for
further improvement to the production of S-MA directly
Figure 1 Schematic representation of S-MA or R-MA biosynthesized from glucose in engineered E. coli. hmaS: Hydroxymandelate
synthase gene from A. orientalis; hmo: Hydroxymandelate oxydase gene from S. coelicolor; dmd: D-mandelate dehydrogenase gene from R.
graminis; E4P: erythrose-4-phosphate; PEP: phosphoenolpyruvate; CHOR: chorismate; HPP: hydroxyphenylpyruvate; DAHP: 3-deoxy-D-arabino-
heptulosonate-7-phosphate.
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shown schematically in Figure 1.
Combined deletion of competing pathways to optimize
the production of S-MA
To further to optimize S-MA production, one logical
possibility is the reduction of the byproducts formed.
Thus, genes involved in competing side reactions would
need to be deleted to avoid the consumption or degra-
dation of the desired intermediates. Since the concentra-
tion of phenylpyruvate was the major limitation in the
synthesis of S-MA, the aromatic amino acid aminotrans-
ferase encoded by tyrB and aspartate aminotransferase
encoded by aspC, which are involved in the conversion
of phenylpyruvate to L-phenylalanine, were deleted to
minimize the loss of phenylpyruvate. The results showed
that the deletion of tyrB increased S-MA production (0.07
g/gDCW) in comparison to the wild-type (0.06 g/gDCW),
whereas the deletion of aspC had no positive effect
on S-MA production (0.05 g/gDCW) and produced
0.92 g/gDCW L-phenylalanine. Furthermore, the produc-
tion of S-MA significantly increased up to 0.15 g/gDCW
(a 2.5-fold increase compared to wild-type), whereas the
byproduct of L-phenylalanine (0.26 g/gDCW) was drama-
tically reduced in double mutants (Figure 3).
To further increase the carbon flux to phenylpyruvate,
the branch pathways of L-tyrosine and L-tryptophan
were disrupted based on tyrB and aspC double mutants
(BC) to reduce divergence from chorismate. Then we
deleted the chorismate mutase/prephenate dehydrogen-
ase encoded by tyrA and the anthranilate synthase
encoded by trpE. As expected, for tyrA or/and trpE
deletion based on double mutants, the production of
S-MA increased to 0.30 g/gDCW (BCAE) with a 2-fold
increase compared to BC and a 5-fold increase com-
pared to wild-type.
We still detected amounts of phenylpyruvate (approxi-
mately 0.02 g/gDCW) that accumulated from BC to
BCAE (Figure 3), which implied that the activity of
HmaS was insufficient to convert all precursors of phe-
nylpyruvate to S-MA. We postulate that combined dele-
tion of the competing pathways led to increased
phenylpyruvate accumulation and resulted in driving
HmaS to synthesize more S-MA. Therefore, HmaS might
be a potential bottleneck for further optimization of
S-MA production and its derivatives.
Figure 3 Biosynthesis of S-MA in different mutants with
pSUFAAQ. Different deletion mutants containing recombinant
pSUFAAQ were cultivated in shake flasks for 24 h. The product
S-mandelic acid, the intermediate phenylpyruvate, and the byproduct
L-phenylalanine were analyzed. Data shown are means ± standard
deviations, calculated from triplicate individual experiments.
Figure 2 Recombinant plasmids constructed in this study. (A) The recombinant plasmid pSUFAAQ used for S-MA synthesis. (B) The
recombinant plasmid pSUFAAQSD used for R-MA synthesis.
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strain BCAE/pSUFAAQ
To further characterize the potential capacity of the best
strain of BCAE harboring pSUFAAQ for S-MA produc-
tion, shake flask fermentation was performed. During
the process of fermentation, the cell density, S-MA pro-
duction, glucose assimilation, and byproduct acetic acid
accumulation were monitored, as shown in Figure 4A
and 4B. As a result, 0.74 g/L S-MA was observed within
24 h, with a yield of 6.5% (g/g) from glucose, which
reached 31% of the theoretical maximum (theoretical
yield is 21% from glucose). The maximum production of
S-MA reached 1.02 g/L within 84 h (Figure 4A) and, at
the same time, glucose was completely consumed
(Figure 4B). The optical isomer of MA in the broth was
identified by HPLC using a chiral column (Additional
file 2), confirming the formation of the S-isomer. Then
the products in the broth were further analyzed by GC-
MS (Additional file 3), confirming the product produced
by recombinant strain BCAE/pSUFAAQ is S-MA.
Therefore, the strain BCAE/pSUFAAQ could be used as
the potential production strain in further studies.
In addition, 1.95 g/L of the byproduct acetic acid was
detected in 24 h, and the titer significantly increased to
6.87 g/L within 84 h (Figure 4B). Acetic acid accumula-
tion could cause many obstacles to the industrial
Figure 4 Time profiles of cell growth, S- or R- mandelic acid production, and residual glucose and acetic acid accumulation during the
culture of the engineered E. coli. (A) OD600, S-mandelic acid produced, and (B) glucose consumed, byproduct acetic acid accumulated were
monitored for BCAE with pSUFAAQ. (C) OD600, R-mandelic acid produced, and (D) glucose consumed, byproduct acetic acid accumulated were
monitored for BCAE with pSUFAAQSD. Data shown are means ± standard deviations calculated from triplicate individual experiments.
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Page 4 of 13production of interesting products. To minimize acetate
formation, many strategies have been developed for this
purpose during E. coli aerobic fermentations [24].
Use of Hmo together with DMD to convert S-MA via
phenylglyoxylate to R-MA in vitro
Thus far, no enzyme with R-mandelate synthase activity
has been identified that could catalyze the precursor of the
amino acid to R-MA. Therefore, to promote fermentation
production of R-MA in vivo, two other enzymes are
required to convert S-MA via phenylglyoxylate to R-MA.
In this study, Hmo from S. coelicolor and DMD from
R. graminis were cloned and expressed in E. coli.T h e n ,
the specific activities of Hmo and DMD were determined
to be 0.257 mU/mg and 87.44 mU/mg, respectively. These
enzymes were used for further studies.
To test whether Hmo together with DMD could trans-
form S-MA to R-MA in vitro,t h e s et w og e n e sw e r e
cloned into a vector of pTrc99a under IPTG inducible
promoter Ptrc resulting in pTrc99aSD. Then an assay for
the simultaneous catalysis of S-MA to R-MA via the
enzymes Hmo and DMD was performed in vitro.A s
shown in Additional file 1, R-MA was detected, but not
for the control (Additional file 1). Thus, the conversion
of S-MA via phenylglyoxylate to R-MA proved the func-
tional expression of these two enzymes in E. coli,a n d
paved the way for further synthesis of R-MA using their
activities in vivo.
Co-expression of hmaS, hmo, and dmd in engineered
E. coli to produce R-MA directly from glucose
fermentation
We have demonstrated that expression of HmaS in
E. coli can ferment glucose to produce S-MA and
proved that the simultaneous expression of Hmo and
DMD can convert S-MA via phenylglyoxylate to R-MA
in vitro. Therefore, we presumed that co-expression of
H m a S ,H m o ,a n dD M Di nE. coli could produce R-MA
from glucose directly.
To produce R-MA ultimately from glucose, a new arti-
ficial biosynthetic pathway was assembled in E. coli.T h e
scheme of this new pathway is shown in Figure 1. Based
on the findings described above, we constructed an artifi-
cial biosynthetic pathway containing HmaS, Hmo, and
DMD, with the corresponding genes obtained from
A. orientalis, S. coelicolor,a n dR. graminis, respectively.
Then, an engineered E. coli strain BCAE with the recom-
binant plasmid pSUFAAQSD (Figure 2B) was created.
Batch cultivations of BCAE/pSUFAAQSD were per-
formed in shake flasks. During the fermentation process,
cell density, R-MA production, glucose assimilation, and
accumulation of the byproduct acetic acid were moni-
tored (Figure 4C and 4D). The results illustrated that
0.68 g/L of R-MA with a yield of 7.8% (g/g)f r o mg l u c o s e
was achieved within 24 h and reached 37% of theoretical
maximum, and the titer of R-MA reached 0.88 g/L in
84 h. The fermentation broth was analyzed by HPLC
equipped with a chiral column (Additional file 2), and
the products were further identified by GC-MS (Addi-
tional file 4). Combining these data showed that the com-
pound in the broth was confirmed as R-MA.
Therefore, in this study we demonstrated that com-
bined expression of the three enzymes in engineered
E. coli strains resulted in the first completely fermenta-
tive synthesis of R-MA directly from glucose.
HmaS might be a potential bottleneck for further
improvement of chiral MA production
To further investigate HmaS as a potential rate-limiting
enzyme preventing further improvement in the yields of
S-MA and R-MA, we cultured BCAE with pSUFAAQ with
various quantities of phenylpyruvate supplied. We found
that the titers of S-MA gradually increased as the concen-
tration of phenylpyruvate increased (Figure 5A). However,
the increase in rate was not remarkable and a maximum of
up to 38% was achieved with 8 mM phenylpyruvate sup-
plied, whereas the cell density declined from OD600 of 6.3
to 4.3, suggesting that the higher concentrations of phenyl-
pyruvate might be toxic to the host. It is also clear that the
yield of S-MA from phenylpyruvate was obviously reduced
from 0.70 (mM/mM) to 0.23 (mM/mM) with a feeding
gradient of 1 mM to 8 mM (shown in Figure 5D). These
results implied that the activity of HmaS was insufficient to
catalyze all supplied phenylpyruvate to S-MA.
Furthermore, the kinetics parameters of HmaS were
measured: the Km of HmaS was 0.45 ± 0.04 mM with
phenylpyruvate as substrate, which was approximately
70-fold greater than the Km with its native substrate 4-
hydroxyphenylpyruvate (6.5 ± 0.8 μM) [25]. This indi-
cates that more phenylpyruvate is needed, compared to
its native substrate, to achieve the same effect for HmaS
synthesis of the corresponding products. Therefore, the
Km of HmaS for phenylpyruvate needs to be modified to
improve the catalytic efficiency at lower phenylpyruvate
concentrations. This would be useful not only in terms
of HmaS competing with other enzymes for catalyzing
phenylpyruvate to S-MA, but would also be beneficial in
alleviating phenylpyruvate toxicity towards the host at
lower concentrations.
Therefore, in combining these data we infer that
HmaS will be an important target for further strain
improvement to enhance S-MA and R-MA production.
Discussion
Chiral mandelic acid, an important medical intermediate,
is mainly prepared by chemical or enzymatic approaches.
In this study, a new fermentative route was created using
an engineered E. coli to produce optical isomers based on
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modified and an artificial pathway using the enzymes
H m a S ,H m o ,a n dD M Df r o mA. orientalis, S. coelicolor,
and R. graminis, respectively, was constructed.
Many enzymatic methods have been reported for the
preparation of stereoisomers [10,13]. However, none of
them were able previously to produce mandelate enan-
tiomers from glucose directly in a single microbial fer-
mentation step. Thus far, substrates of enzymatic routes
such as benzaldehyde and mandelonitrile have not been
identified among the microbial primary metabolic path-
ways. If in the future some enzymes are discovered for
catalyzing the primary metabolites to benzaldehyde or
mandelonitrile, such multistep enzyme-catalyzed pro-
cesses might be developed in the microbe for the pro-
duction of mandelate isomers from glucose. However,
the conversion rate would not be superior to that in this
report due to the requirement for more heterogeneous
enzymes and the extra reaction steps required.
Due to a lack of R-mandelate synthase, which could
catalyze phenylpyruvate to R-MA directly, a relatively
complex artificial pathway was constructed in this work
for the production of R-MA. If R-mandelate synthase
were available, the method for preparation of R-MA
Figure 5 Biosynthesis of S-mandelic acid with phenylpyruvate supplied. Products of engineered strains BCAE with pSUFAAQ fed with
various concentrations of phenylpyruvate were analyzed in shake flasks during 24 h. S-mandelic acid, L-phenylalanine, and phenylpyruvate (A),
cell growth (B), glucose consumption (C), and yields of S-mandelic acid from supplied phenylpyruvate (D) are listed. Data shown are means ±
standard deviations calculated from triplicate individual experiments.
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synthase only. We tried to find this kind of enzyme in
some microorganisms using bioinformatics means.
Unfortunately, thus far we have not been able to find it
due to limited resources; however, it should be possible
to construct enzymes with R-mandelate synthase activity
through directed evolution.
Although we have successfully achieved the prepara-
tion of S-MA and R-MA in engineered E. coli,t h e
byproduct of L-phenylalanine was still formed by the
double mutant. It could be that the branched-chain
amino acid aminotransferase encoded by ilvE is able to
catalyze phenylpyruvate to L-phenylalanine [26], so the
deletion of ilvE should eliminate L-phenylalanine forma-
tion to optimize the production of S-MA and R-MA in
the future.
We observed the accumulation of large quantities of
acetic acid during the fermentation process (Figure 4B
and 4D). Acetic acid excretion by E. coli during aerobic
growth on glucose is a major obstacle to recombinant
protein production and chemical products, and gene dis-
ruptions have been successfully employed to minimize
acetic acid formation and increase the production level of
desired chemicals [27-30]. In this work, to improve MA
production, we have deleted acetate-forming genes
including poxB, pta, ackA,a n dacs to reduce acetic acid
formation. Results showed that single gene deletions did
not reduce acetate accumulation, suggesting that alterna-
tive pathways were also involved in acetate production
(Additional file 5). As expected, simultaneous deletion of
poxB, ackA and acs greatly minimized acetate accumula-
tion (Additional file 6). However, the acetate reduction
led to no increase in the carbon flux to MA production,
which might be caused by significantly reduced cell
growth rates.
In order to improve the production of S-MA, two
genes (ppsA and tktA) [31] were co-expressed in the
engineered S-MA-producing strains to enhance the sup-
ply of precursors of PEP and E4P. In the resulting strains
the productivity of S-MA improved whereas the titer did
not improve (data not shown). This result indicated that
some other bottleneck exists downstream of the S-MA
synthesis pathway.
HmaS is not only a key enzyme for S-MA synthesis but
is also the first step in R-MA synthesis. We have pre-
viously investigated the effects of different mutants on S-
MA production. The results implied that the activity of
HmaS was insufficient to convert all phenylpyruvate to
S-MA, leading to the accumulation of phenylpyruvate in
the culture. To further explore the activity of HmaS, we
also conducted phenylpyruvate feeding experiments.
Although higher concentrations of phenylpyruvate
slightly enhanced the yield of S-MA, the conversion rate
of HmaS was significantly reduced with increasing
phenylpyruvate. Furthermore, we measured the kinetic
parameters of HmaS and found that its affinity towards
the non-natural substrate phenylpyruvate was much
lower than that towards its natural substrate [25]. This
suggests that, in order to synthetize S-MA, HmaS needs
a higher concentration of the substrate phenylpyruvate as
the driving force. Therefore, combining these data we
infer that HmaS will potentially be the bottleneck for
further improvement of S-MA and R-MA synthesis.
Thus, the catalytic activity of HmaS for converting phe-
nylpyruvate to S-MA should be improved first through
protein engineering to further improve the titers and
yields of S-MA and R-MA production.
Conclusions
We have established a functional artificial pathway in
E. coli and developed the first completely fermentative
route for producing optically pure S-MA and R-MA from
glucose, though further strain improvement and fermenta-
tive process optimization, including metabolic flux analy-
sis, will be needed to improve the production of S-MA
and R-MA. The successful construction of S-MA- and R-
MA-producing E. coli in this study provides a solid basis
for the development of other engineered bacteria, which
could yield other commercially attractive bio-products or
their derivatives from renewable resources.
Methods
Bacterial strains and culture media
Strains and plasmids used in this study are listed in Table 1.
Antibiotics were used when needed at the following con-
centrations: Ampicillin (100 mg/L), Chloramphenicol
(25 mg/L), Kanamycin (50 mg/L), Tetracycline (15 mg/L),
Spectinomycin (50 mg/L), Apramycin (50 mg/L).
LB medium was used for culturing the general strains
for cloning. The engineered E. coli strains were culti-
vated in shake flasks in fermentation medium to test S-
or R-MA production in vivo.
The fermentation medium contained the following
components: D-glucose (20 g/L), KH2PO4 (1.0 g/L),
(NH4)2SO4 (16 g/L), MgSO4 7H2O( 1 . 0g / L ) ,L - t y r o s i n e
(0.2 g/L), L-tryptophan (0.1 g/L), L-aspartic acid (3 g/L),
FeSO4 7H2O (0.01 g/L), MnSO4 H2O (0.008 g/L), CaCO3
(20 g/L). The stock solution of D-glucose, CaCO3,a n d
MgSO4 was autoclaved separately whereas L-tryptophan,
FeSO4, and MnSO4 were sterilized using a 0.22-μm filter.
Plasmid construction
The gene encoding feedback resistant mutant aroF
fbr
P148L [22] including the native promoter was obtained by
overlap PCR, and the genomic DNA of E. coli W3110 was
used as the PCR template. Two overlapping DNA frag-
ments were amplified using primer pairs P148L-F/aroF-
SacI-R and P148L-R/aroFSacI-F, respectively. Then, using
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another PCR reaction was performed with primer pair
aroFSacI-F/aroFSacI-R and the whole length mutant
aroF
fbr gene was obtained. The resulting product was
digested with Sac I and cloned into pSU2718 cut with the
same enzyme, creating pSUaroF
fbr.
The gene encoding feedback resistant mutant pheA
fbr
G309C [23] was constructed with the primers pheA-M-
F/pheA-M-R and pheA-MN-FM/pheA-M-RM using
overlap PCR (as described above). The purified PCR
fragments of mutant pheA
fbr were double digested with
EcoRIa n dHind III and then cloned into pKK223-3,
creating pKKpheA
fbr.T h e nt h eg e n epheA
fbr with the
promoter Ptac and RBS (ribosome binding site) was
amplified from pKKpheA
fbr with primers PTacpheA*-F
and PTacpheA*-R. The resulting PCR product was
ligated into pSUaroF
fbr vector, creating pSUFA.
The gene lacI
q was amplified from pTrc99a with pri-
mers lacI
q-F and lacI
q-R. Then, it was cut with Nhe I
and ligated into the same site of pSUFA, creating
pSUFAQ.
The gene hmaS was amplified from the genomic DNA
of A. orientalis HCCB10007 (GenBank: HQ679900)
using the primers hmaSAo-F and hmaSAo-R. The PCR
fragments were digested with Nde Ia n dHind III, and
cloned into pET24a vector, generating pEThmaSAo.
Table 1 Strains and plasmids used in this study
Strains Genotype Reference
A. orientalis
HCCB10007
Vancomycin-producing bacteria [37]
S. coelicolor
A3(2) M145
Wild type SCP1
- SCP2
- [38]
R. graminis
ATCC20804
Rhodotorula graminis di Menna, anamorph, mutant derived from KGX39 ATCC
DH5a lacZΔM15 endA1 recA1 relA1 gyrA96 deoR nupG l
- TaKaRa
JM105 endA1 glnV44 sbcB15 rpsL thi-1 Δ(lac-proAB) [F’ traD36 proAB
+ lacI
q lacZΔM15] hsdR4( r K
-mK
+) Pharmacia
BL21(DE3) F
- omp gal dcm lon hsdSB (rB
-mB
-) l(DE3) Novagen
JW1256-1 F
- l
- ΔlacZ4787 (::rrnB-3), ΔtrpE::FRT-kan-FRT, rph-1 hsdR514 CGSC
N3087 tyrA16::Tn10 rpsL31(str
R) CGSC
WT Wild type E. coli W3110 F
- l
- rph-1 INV (rrnD rrnE) CGSC
B W3110 ΔtyrB::FRT This study
C W3110 ΔaspC::FRT This study
BC W3110 ΔtyrB::FRT, ΔaspC::FRT This study
BCA W3110 ΔtyrB::FRT, ΔaspC::FRT, tyrA16::Tn10 This study
BCE W3110 ΔtyrB::FRT, ΔaspC::FRT, ΔtrpE::FRT This study
BCAE W3110 ΔtyrB::FRT, ΔaspC::FRT, tyrA16::Tn10, ΔtrpE::FRT This study
Plasmids Genotype Reference
pET24a kan PT7 expression vector Novagen
pEThmaSAo pET24a derivative, hmaSAo from A. orientalis This study
pET24admd pET24a derivative, dmd from R. graminis This study
pTrc99a bla Ptrc lacI
q pBR322 ori expression vector Pharmacia
pTrc99ahmo pTrc99a derivative, hmo This study
pTrc99aSD pTrc99a derivative, hmo, dmd This study
pKK223-3 bla Ptac pBR322 ori expression vector Pharmacia
pKKpheA
fbr pKK223-3 derivative, pheA
fbr from E. coli This study
pSU2718 Hae II fragment of pUC18 containing lacZa and MCS, p15A replicon with chloramphenicol acetyl transferase gene (cat) [39]
pSUaroF
fbr pSU2718 derivative, aroF
fbr from E. coli This study
pSUFA pSU2718 derivative, aroF
fbr, pheA
fbr This study
pSUFAQ pSU2718 derivative, aroF
fbr, pheA
fbr, lacI
q This study
pSUFAAQ pSU2718 derivative, aroF
fbr, pheA
fbr, lacI
q, hmaSAo This study
pSUFAAQSD pSU2718 derivative, aroF
fbr, pheA
fbr, lacI
q, hmaSAo, hmo, dmd This study
pIJ790 araC ParaBAD gam bet exo repA101
ts oriR101 cat [33]
pIJ773 bla FRT-aac(3)IV-oriT-FRT [33]
pIJ778 bla FRT-aadA-oriT-FRT [33]
BT340 t
s bla cat [33]
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Page 8 of 13hmaS with the RBS of pET24a was amplified by PCR
using primers pETrbs+hmaSAo-F and pETrbs+hmaSAo-
R. The corresponding PCR fragments were purified and
cut with Sal Ia n dBamH I, then cloned into pSUFAQ,
generating the recombinant plasmid pSUFAAQ for the
production of S-MA (the scheme of plasmid pSUFAAQ
can be seen in Figure 2A).
The gene hmo was amplified from the genomic DNA
of S. coelicolor A3(2) M145 (GenBank: AL939115) with
the primers hmo-F and hmo-R. The PCR fragments
were purified, then digested with Nco Ia n dKpn I, and
cloned into pTrc99a vector, creating pTrc99ahmo.
The gene dmd was amplified from the total cDNA of R.
graminis ATCC20804 (GenBank: AJ001428) with the pri-
mers dmd-F and dmd-R, and cloned into the Nde Ia n d
EcoR I sites of pET24a to create pET24admd. Then, the
fragments including dmd gene and the RBS of pET24a
were amplified with the primers pETrbs+dmd-F and
pETrbs+dmd-R. The corresponding PCR fragments were
cloned into the Kpn Ia n dPst I sites of pTrc99ahmo to
generate pTrc99aSD. Then the DNA fragments contain-
ing genes hmo and dmd with Ptrc promoter were
obtained by PCR with the primers pTrcSD-F and
pTrcSD-R, and inserted into the BamHIs i t eo fp S U -
FAAQ to create pSUFAAQSD for the production of
R-MA (the scheme of plasmid pSUFAAQSD can be seen
in Figure 2B).
Plasmids were isolated using the AxyPrep Plasmid
Miniprep Kit (Axygen, Hangzhou, China). AxyPrep
DNA Gel Extraction Kit was used to isolate DNA frag-
ments from agarose gels (Axygen, Hangzhou, China).
All PCR fragments were sequencing identified by Bio-
Sune (Shanghai, China). DNA polymerase KOD plus for
PCR reactions was purchased from ToYoBo (Shanghai,
China). All restriction enzymes and Taq DNA polymer-
ase were purchased from Fermentas (Shanghai, China).
Rapid DNA ligase and alkaline phosphatase were
obtained from TaKaRa (Shanghai, China). Oligonucleo-
tides were ordered from BioSune (Shanghai, China).
The plasmids constructed in this work are listed in
Table 1, and the oligonucleotides used are given in
Table 2.
Construction of deletion mutants of E. coli
The deletion mutants of genes aspC and tyrB were
obtained by a one-step inactivation protocol [32]. The
disruption cassettes were amplified from vector pIJ773
or pIJ778 by PCR and then transformed into E. coli
W3110 that contained the plasmid pIJ790 [33]. The
resulting strain with the apramycin resistant cassette
Table 2 Primers used for gene cloning in this study
Primer Name Nucleotide Sequence Restriction site
P148L-F 5’-TTAGATCTGAATAGCCCGCAATACCTGGGC- 3’
P148L-R 5’-GCTATTCAGATCTAACGCTTCCGTCGCCAGTGG - 3’
aroFSacI-F 5’-AACGAGCTCACCGGAAAGTCCTCGGGCATAAG - 3’ Sac I
aroFSacI-R 5’-AACGAGCTCCGACTTCATCAATTTGATCGCGTAA - 3’ Sac I
pheA-M-F 5’-GGGAATTCTATGACATCGGAAAACCCGTTAC - 3’ EcoRI
pheA-M-R 5’- ATCCGGAAGCTTTTCATCAGG - 3’ Hind III
pheA-MN-FM 5’- AACAAGCCTGTGCGCTGG - 3’
pheA-M-RM 5’- TCAACCAGCGCACAGGCTTGTTGC - 3’
PTacpheA*-F 5’- GATCCGAAGCTTATCGACTGCACG - 3’ Hind III
PTacpheA*-R 5’-A GTCGACGCTTTTCATCAGGTTGG - 3’ Sal I
lacI
q-F 5’-C GCTAGCCCTGACGGGCTTGTCTG - 3’ Nhe I
lacI
q-R 5’-C GCTAGCTTCCGATGGCTGCCTG - 3’ Nhe I
hmaSAo-F 5’-C G CATATGCAGAATTTCGAGATCGACTAC - 3’ Nde I
hmaSAo-R 5’-C AAGCTTAACGTACGTCATCGCCG - 3’ Hind III
hmo-F 5’-GATATACCATGGGCAGCAGCCATC-3’ Nco I
hmo-R 5’-CGGTACCTGGTCATCCGTGGCTCCTG-3’ Kpn I
pETrbs+hmaSAo-F 5’-C C GTCGACAAATAATTTTGTTTAACTTTAAG - 3’ Sal I
pETrbs+hmaSAo-R 5’- CGGCCGGATCCTTGAAGATCTC - 3’ BamHI
dmd-F 5’-CCATATGCCTCGCCCTCGCGTC-3’ Nde I
dmd-R 5’-GGAATTCAGTAGGCGCGAAAAGCG-3’ EcoRI
pETrbs+dmd-F 5’-CGGTACCTTTGTTTAACTTTAAGAAGG-3’ Kpn I
pETrbs+dmd-R 5’-ACTGCAGTGGTGGTGGTGGTGGTGCT-3’ Pst I
pTrcSD-F 5’-AGGATCCAAATCACTGCATAATTCG-3’ BamHI
pTrcSD-R 5’-TGGATCCGTTATTGTCTCATGAGCG-3’ BamHI
Underlined text denotes the restriction site sequences, and bold type indicates the start condons.
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Page 9 of 13inserted into the gene aspC site was designated as
W3110ΔaspC.T h etyrB deleted mutant W3110ΔtyrB
was constructed using the spectinomycin resistant cas-
sette by the method described above. Then the multi-
deletion mutants were generated by P1 transduction
[34] from these single-deletion mutants. The P1 phage
lysate prepared from W3110ΔaspC was used to infect
W3110ΔtyrB to produce double-deletion mutant
W3110Δ(tyrB, aspC). Using the same protocol, we suc-
cessfully obtained tri-deletion mutants of W3110Δ(tyrB,
aspC, trpE) and W3110Δ(tyrB, aspC, tyrA) by transfer of
trpE mutation from JW1256-1 or tyrA mutation from
N3087 using P1 phage to W3110Δ(tyrB, aspC), respec-
tively. W3110Δ(tyrA, tyrB, aspC, trpE) was generated by
transfer of tyrA mutation from N3087 to W3110Δ(tyrB,
aspC, trpE). The disruption cassettes of aspC::FRT-apra-
FRT, tyrB:: FRT-spec-FRT, trpE:: FRT-kan-FRT were
eliminated by pCP20 [33], except for tyrA16::Tn10.
Then the resistance markers of W3110ΔaspC,
W3110ΔtyrB, W3110Δ(tyrB, aspC), W3110Δ(tyrB, aspC,
trpE), W3110Δ(tyrB, aspC, tyrA), and W3110Δ(tyrA,
tyrB, aspC, trpE) were removed using FLP-mediated
excision of the disruption cassette [33], resulting in
strains C, B, BC, BCE, BCA, and BCAE, respectively. All
deletion mutants were verified by PCR analysis. All of
the E. coli mutants constructed in this study are
described in Table 1, and the primers used are listed in
Table 3.
Preparation of cell extract for enzymatic assays
E. coli BL21(DE3) strains harboring the plasmids pEThma-
SAo, pET24admd, pTrc99ahmo or pTrc99aSD were culti-
vated in tubes containing 4 mL LB medium with
appropriate antibiotics at 37°C at 220 rpm overnight. Then
0.5 mL of culture broth were added to 50 mL of LB med-
ium in 250-mL shake flasks that contained appropriate
antibiotics at 30°C at 220 rpm. When OD600 reached
0.4~0.6, the cells were induced by addition of 1 mM iso-
propyl b-D-1-thiogalactopyranoside (IPTG). After 4 h, cells
were harvested and washed with 200 mM potassium phos-
phate buffer (pH 7.5). Then the cell pellet was resuspended
in 5 mL 200 mM potassium phosphate buffer (pH 7.5),
and the cells were disrupted by French Press (Constant cell
disruption systems, United Kingdom) at 25 kpsi. The lysate
was centrifuged at 12000 rpm for 20 min (Eppendorf Cen-
trifage 5810R) and the supernatant was used to determine
activity. As a control, E. coli BL21(DE3) containing plasmid
pET24a or pTrc99a was treated in the same manner. The
total protein concentration of the supernatant was deter-
mined by the Bradford method [35], using bovine serum
albumin (BSA) as a standard.
Enzyme assays
The HmaS assay was performed as described previously
[19], with the exception that the 5-mL reaction mixture
contained 200 mM potassium phosphate buffer (pH 7.5),
5 mM phenylpyruvate, 44 mM ascorbate, 0.3 mM FeSO4,
and a final concentration of 1 mg/mL of soluble protein.
The reaction was started by the addition of the cell-free
extract at 28°C. After addition of 100 μL1MH C lt o
500-μL samples to stop the reaction, the solution was
centrifuged at 12000 rpm for 5 min (Eppendorf Centrif-
age 5430), and the products were analyzed by HPLC.
The Hmo and DMD assays were performed as
described previously [19,20].
Production of R-MA in vitro
In the assay for R-MA production in vitro, the 5-mL reac-
tion mixture contained 200 mM potassium phosphate buf-
fer (pH 7.5), 5 mM S-MA, 2 mM NADH, 40 mM NAD
+,
and a final concentration of 1 mg/mL of soluble protein.
The reaction was started by the addition of the crude
Table 3 Primers used for gene deletion and verification in this study
Primer Name Nucleotide Sequence Characterization
tyrB-KO-F 5’-TTTAACCACCTGCCCGTAAACCTGGAGAACCATCGCGTGATTCCGGGGATCCGTCGACC- 3’ Deletion primer
tyrB-KO-R 5’-ACTGCAGGCTGGGTAGCTCCAGCCTGCTTTCCTGCATTATGTAGGCTGGAGCTGCTTC- 3’ Deletion primer
tyrB-V-F 5’- CTGTTGCTAATTGCCGTTCG - 3’ Verification primer
tyrB-V-R 5’- CACGTAGAACGATGGCATCA - 3’ Verification primer
aspC-KO-F 5’-CGGACTTCCCTTCTGTAACCATAATGGAACCTCGTCATGATTCCGGGGATCCGTCGACC- 3’ Deletion primer
aspC-KO-R 5’-AGCCCGCTTTTCAGCGGGCTTCATTGTTTTTAATGC TTATGTAGGCTGGAGCTGCTTC- 3’ Deletion primer
aspC-V-F 5’ - CCTGCGTTTTCATCAGTAATAGTTGG - 3’ Verification primer
aspC-V-R 5’ - CCTTATCCGGCCTACAAAATCG - 3’ Verification primer
tyrA-V-F 5’ - TATCCGTAACCGATGCCTGC - 3’ Verification primer
tyrA-V-R 5’ - GGGAAATCACCCGTTCAATG - 3’ Verification primer
trpE-V-F 5’ - CGTACTGAAAGGTTGGTGGCG - 3’ Verification primer
trpE-V-R 5’ - AGGAGAAAGCATCAGCACCG - 3’ Verification primer
Italics represent the sequences homologous to the gene to be deleted, underlined text denotes the sequence homologous to plasmid pIJ773 or pIJ778 for
amplification of the resistance cassette.
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Page 10 of 13extract at 30°C. Following the addition of 100 μL1MH C l
to 500-μL samples to stop the reaction, the solution was
centrifuged at 12000 rpm for 5 min (Eppendorf Centrifage
5430), and the supernatants were analyzed by HPLC.
Production of S- or R-MA in vivo
The engineered strains BCAE containing the plasmid
pSUFAAQ or pSUFAAQSD were inoculated into 4 mL
LB medium with chloramphenicol (25 mg/L) and incu-
bated at 37°C at 220 rpm overnight. 4 mL of this culture
were subsequently added to 250-mL shake flasks contain-
ing 50 mL of the fermentation medium with chloramphe-
nicol (25 mg/L) and incubated at 37°C, 220 rpm. After
4~5 h incubation when the OD600 had reached 0.4~0.6,
the cells were induced by adding 0.1 mM IPTG, and then
the temperature was set to 33°C. Samples were taken at
different time points during cultivation and centrifuged at
4°C at 12000 rpm for 5 min (Eppendorf Centrifage 5430).
Then the supernatant was frozen at -20°C and prepared
for analysis by HPLC, GC, and GC-MS. Cell densities
were determined by spectrophotometer OD600 (Beckman
coulter DU730, USA). Dry cell weight (g/L) was calculated
using a conversion coefficient of 0.375 g/L/OD600.
Phenylpyruvate feeding experiments
To test HmaS conversion of phenylpyruvate to S-MA in
vivo, feeding experiments were performed. The concentra-
tion gradient was as follows: 0 mM, 1 mM, 2 mM, 4 mM,
and 8 mM. The phenylpyruvate was fed when the OD600
reached 0.4~0.6, meanwhile 0.1 mM IPTG was added to
the cultures inducing expression of HmaS, and the fer-
mentation temperature was adjusted from 37°C to 33°C
for 24 h. Culture samples were analyzed by HPLC.
HPLC analysis
L-phenylalanine, phenylpyruvate, and S- or R-MA were
quantified using a high-performance liquid chromatogra-
phy system (Agilent Technologies 1,100 series) equipped
with a Zorbax Eclipse XDB-C8 column (Agilent, 4.6 mm
× 150 mm, 5 μm) at 40°C. The mobile phase consisted of
50 mM phosphate sodium buffer (pH 6.5) and methanol
at a volume ratio of 95:5, at a flow rate of 1 mL/min, with
UV detection was 215 nm. The pure substances were
used as standards.
The S- or R-MA was identified by HPLC with a CHIR-
ALCEL OD-H column (4.6 mm × 250 mm, 5 μm; Daicel
Co., Japan) at 30°C. The mobile phase consisted of hexane,
isopropanol, and trifluoroacetic acid in a volume ratio of
94:6:0.2, at a flow rate of 1.2 mL/min, and the UV detec-
tion wavelength was 228 nm. The pH of samples was
adjusted to 1~2 using HCl, then S- or R-MA in the broth
was extracted using an equal volume of ethyl acetate.
Glucose concentrations in the broth were determined
by HPLC (Model 1200, Agilent) using a Sugar-Pak TM I
column (Waters Corp., MA, USA), and the refractive
index detector was used [36].
Standard samples were racemic mandelic acid ordered
from Fluka, L-phenylalanine from Tokyo Chemical
Industry (TCI, Shanghai, China), and phenylpyruvate
(sodium), S-MA, and R-MA from Sigma.
GC analysis
The concentration of acetic acid in the supernatant was
determined using gas chromatography (GC) (7890A,
Agilent, Wilmington, DE, USA)[36].
GC-MS analysis
S- or R-MA was further identified by gas chromatography-
mass spectrometry (GC-MS). Lyophilized samples were
oximated with 20 mg/mL methoxyamine hydrochloride in
pyridine at 30°C for 60 min. Then 80 μLp y r i d i n ea n d
20 μL N-methyl-N-[tert-butyldimethylsilyl] trifluoroaceta-
mide were added to the samples for derivatization at 70°C
for 30 min. Then 3 μL of derivatized sample were injected
for GC-MS analysis after filtration. The GC-MS system
(Agilent 6890-5973) was equipped with an HP-5MS col-
umn (30 m, 0.25 mm, 0.25 μm), and the electron impact
(EI) mode of the mass spectrometer was set to 70 eV. The
GC oven temperature was initially held at 60°C and raised
with a gradient of 5°C per minute until it reached 180°C.
It was then raised with a gradient of 10°C per minute until
it reached 260°C. The flow rate of the mobile phase was
set to 1 mL/min. All reagents used in this assay were
ordered from Sigma.
Additional material
Additional file 1: Chiral chromatography of the MA produced in
vitro. (a) racemic mixture standards; (b) BL21(DE3) with pET24a as
negative control; (c) HmaS stereoconversion of phenylpyruvate to S-MA;
(d) BL21(DE3) with pTrc99a as negative control; (e) Hmo and DMD
together transform S-MA to R-MA.
Additional file 2: Chiral chromatography of the MA produced in
vivo. (f) racemic mixture standards; (g) the fermentation broth of BCAE
with pSUFAQ as negative control; (h) S-MA synthesized by strains BCAE
harboring pSUFAAQ; (i) R-MA synthesized by strains BCAE containing
pSUFAAQSD.
Additional file 3: GC-MS analysis of the S-MA produced in vivo.S -
MA in the broth was further verified by GC-MS: (a) the total ion
chromatogram of S-MA; (b) the m/z profile of S-MA; (c) the standard m/
z profile of MA from the GC-MS library.
Additional file 4: GC-MS analysis of the R-MA produced in vivo.R -
MA in the broth was further verified by GC-MS: (a) the total ion
chromatogram of R-MA; (b) the m/z profile of R-MA; (c) the standard m/
z profile of MA from the GC-MS library.
Additional file 5: Cell densities, acetate and S-MA concentrations in
LB medium with glucose. All single gene mutants and the control
strain (BCAE) were cultured in LB medium supplemented with 20 g/L
glucose for 48 h. All of the strains harbor the plasmid pSUFAAQ. ND: not
detected.
Additional file 6: Cell densities, acetate and S-MA concentrations in
fermentation medium. The triple genes mutant and control strain
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Page 11 of 13(BCAE) were grown in fermentation medium for 48 h. Both of the strains
harbor the plasmid pSUFAAQ. Data shown are means ± standard
deviations, calculated from triplicate individual experiments.
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